

Table S3. Adverse events (from inclusion to 14 days after ended treatment)

		Faecal microbiota transplantation (n=34)	Rectal bacteriotherapy (n=31)			Only vancomycin (n=31)
During procedure /observation	Potentially related	GI-symptoms, 28 of 34 participants: Defaecation urge, 20; Abdominal pain or discomfort, 15; Fecal incontinence, 8; Borborygmi, 7; Nausea or vomiting, 5 Other, 1 of 34 participants: Cold sweat, 1	GI-symptoms, 11 of 31 participants: Defaecation urge, 5; Fecal incontinence, 3; Abdominal pain or discomfort, 1; Rectal discomfort, 1; Borborygmi, 1 Other, 1 of 31 participants: Chills, General discomfort and Left-side pain from procedure positioning, 1	During treatment	Potentially related	Adverse reactions known to vancomycin, 6 of 31 participants: Itching or rash, 3; Dizziness, 2; Dyspnoea, 1; Hypotension, 1 GI-symptoms, 9 of 31 participants: Nausea, 3; Loss of appetite, 3; Bloating, 2; Abdominal pain or discomfort, 1; Diarrhea, 1; Constipation, 1 Other, 6 of 31 participants: Fatigue, 5; Oedema, 1
	Unrelated	Other, 1 of 34 participants: Hypoglycaemia	None		Unrelated	GI-symptoms, 4 of 31 participants: Abdominal pain or discomfort, 1; Diarrhea, 1; Increased liver enzymes, 1; Minor rectal bleeding, 1 Other, 6 of 31 participants
Within 48 hours after ended treatment	Potentially related	GI-symptoms, 25 of 34 participants: Bloating, 12; Abdominal pain or discomfort, 11; Flatulence, 7; Diarrhea, 5; Borborygmi, 4; Nausea or vomiting, 4; Fecal incontinence, 1; Belching, 1; Rectal pain at defaecation, 1 Other, 6 of 34 participants: Fatigue, 5; Headache, 2; Fever, 2; Dizziness, 1 Infections, 1 of 34 participants: Urinary tract infection	GI-symptoms, 26 of 31 participants: Abdominal pain or discomfort, 18; Diarrhea, 14; Borborygmi, 9; Bloating, 16; Nausea or vomiting, 5; Flatulence, 3; Fecal incontinence, 2; Anal itching, 1; Belching, 1; Defaecation urge, 1; Heartburn, 1; Minor rectal bleeding, 1; Rectal discomfort, 1 Other, 8 of 31 participants: Fatigue, 3; Fever or feeling feverish, 3; Back pain after procedure positioning, 2; Chills, 2; Headache, 1; Dizziness, 1; General discomfort, 1	After treatment	Potentially related	GI-symptoms, 1 of 31 participants: Diarrhea, 1
	Unrelated	GI-symptoms, 1 of 34 participants: Mild hematemesis after coughing, 1 Other, 5 of 34 participants: Epistaxis, 2; Non-malignant process on the neck, 1; Rash in the pelvic region, 1; Cough, 1; Epileptic seizure, 1	Other, 4 of 31 participants: Musculoskeletal pain, 2; Oedema, 1; Dyspnoea, 1; Rash in the pelvic region, 1		Unrelated	Adverse reactions known to vancomycin, 2 of 31 participants: Itching, 1; Back pain, 1 GI-symptoms, 3 of 31 participants: Abdominal pain or discomfort, 2; Mucous stool, 1; Diarrhea, 2 Other, 5 of 31 participants

Adverse events - continued						
		Faecal microbiota transplantation (n=34)	Rectal bacteriotherapy (n=31)			
After 48 hours after ended treatment	Potentially related	GI-symptoms, 11 of 34 participants: Abdominal pain or discomfort, 6; Diarrhea, 5; Constipation, 4; Bloating, 2; Defaecation urge, 1; Reflux, 1 Other, 2 of 34 participants: General discomfort, 1; Feeling feverish, 1	GI-symptoms, 17 of 31 participants: Diarrhea, 8; Abdominal pain or discomfort, 6; Bloating, 3; Belching, 2; Constipation, 2; Mucous stool, 2; Borborygmi, 1; Fecal incontinence, 1; Defaecation urge, 1 Infections, 1 of 31 participants: Urinary tract infection			
	Unrelated	GI-symptoms, 1 of 34 participants: Reflux Infections, 3 of 34 participants: Common cold, 2; Conjunctivitis, 1 Other, 7 of 34 participants: Mental distress, 2; Dyspnoea, 1; Itching, 1; General discomfort, 1; Chest pain, 1; Rhinorrhoea, 1; Discomfort after vaccination, 1	GI-symptoms, 2 of 31 participants: Loss of appetite Infections, 2 of 31 participants: Common cold, 1; Herpes Labialis, 1 Other, 8 of 31 participants: Musculoskeletal pain, 3; Fatigue, 2; Cough, 1; Urine incontinence, 1; Dizziness, 1; Mental distress, 1; Dysfunctional nephrostomy catheter, 1; Groin pain, 1			
Serious adverse events (from inclusion to 14 days after ended treatment)						
		Faecal microbiota transplantation (n=34)	Rectal bacteriotherapy (n=31)		Only vancomycin (n=31)	
During pre-treatment with oral vancomycin	Requires hospitalization	Unrelated, 1 of 34 participants: Severe dizziness	No serious adverse events		During treatment	Potentially related, 1 of 31 participants: Oedema, dyspnoea and fever
						Unrelated, 3 of 31 participants: Diarrhea, loss of appetite and mental distress, 1; Syncope leading to car crash after dialysis, 1; Pneumonia, 1
During or after FMT/RBT	Requires hospitalization	No serious adverse events	Potentially related, 1 of 31 participants: Urosepsis, 1		After treatment	Unrelated, 1 of 31 participants: Chronic subdural haematoma
			Unrelated, 2 of 31 participants: Chest pain, 1; Dehydration, 1			Results in death

Table. Adverse events (from inclusion to 14 days after treatment).

Adverse events: Any adverse event/ untoward medical occurrences in participants with or without a causal relationship with the trial treatment. Adverse reactions: an adverse event with a causal relation to the trial treatment. Serious adverse event: An adverse event or reaction that results in death, is life-threatening, requires inpatient hospitalization or prolonged hospitalization, or results in persistent or significant disability or congenital anomaly/birth defect.